Cardiovascular Effects of L-158,809, a New Angiotensin Type 1 Receptor Antagonist, Assessed Using the Halothane-Anesthetized In Vivo Canine Model.
-
- Yoneyama Masahiko
- Department of Pharmacology, Yamanashi Medical University
-
- Sugiyama Atsushi
- Department of Pharmacology, Yamanashi Medical University
-
- Yoshida Hiroshi
- Department of Pharmacology, Yamanashi Medical University
-
- Satoh Yoshioki
- Department of Pharmacology, Yamanashi Medical University
-
- Hashimoto Keitaro
- Department of Pharmacology, Yamanashi Medical University
Search this article
Abstract
L-158,809 is a new angiotensin II type 1 receptor antagonist. We simultaneously assessed its antagonistic potency and cardiovascular effects with the halothane-anesthetized in vivo canine model (n = 5). L-158,809 was intravenously infused over 10 min at escalating doses of 0.03, 0.3 and 3 mg/kg. Angiotensin II (0.1 μg/kg, i.v.)-induced vasopressor and negative inotropic responses were significantly suppressed from the low dose L-158,809. Meanwhile, L-158,809 did not affect any of the cardiovascular parameters except that QTc was slightly shortened after the high dose administration. These results support the previous in vitro knowledge that L-158,809 is a highly selective angiotensin II receptor antagonist.
Journal
-
- The Japanese Journal of Pharmacology
-
The Japanese Journal of Pharmacology 89 (2), 192-196, 2002
The Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679262649088
-
- NII Article ID
- 10008684253
-
- NII Book ID
- AA00691188
-
- COI
- 1:STN:280:DC%2BD38znsFOmtA%3D%3D
-
- ISSN
- 13473506
- 00215198
-
- NDL BIB ID
- 6262145
-
- PubMed
- 12120764
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed